


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1-38. (Cancelled)

39. (New) A method for treating an individual with a tumor resistant or refractory to a taxane, comprising administering to the individual an effective amount of a compound of the structure




40. (New) The method according to claim 39, wherein the resistance or refractoriness of said cancer or tumor is mediated through tubulin.
41. (New) The method according to claim 39, wherein the resistance or refractoriness of said cancer or tumor is mediated through multidrug resistance.
42. (New) The method according to claim 41, wherein said multidrug resistance is mediated through overexpression of an ABC transporter.
43. (New) The method according to claim 39, wherein said taxane is paclitaxel.
44. (New) The method according to claim 39, wherein said taxane is docetaxel.
45. (New) The method according to claim 39, wherein said tumor comprises a solid tumor.
46. (New) The method of claim 45, wherein said solid tumor is selected from: breast cancer, cervical cancer, colorectal cancer, peritoneal cancer, ovarian cancer, bronchial cancer, small cell lung cancer, non-small cell lung cancer, gastric, prostate, and head and neck cancer, or metastases thereof.
47. (New) The method of claim 45, wherein said solid tumor is prostate cancer.

48. (New) The method of claim 45, wherein said solid tumor is breast cancer.
49. (New) The method of claim 45, wherein said solid tumor is ovarian cancer.
50. (New) The method of claim 45, wherein said solid tumor is non-small cell lung cancer.
51. (New) The method according to claim 39, wherein said tumor comprises a hematological tumor.
52. (New) The method according to claim 39, wherein said method results in killing or inhibition of growth of a tumor cell comprised in said tumor resistant or refractory to a taxane.
53. (New) The method according to claim 39, wherein said method further comprises the further administration of an effective amount of another pharmaceutical ingredient or exposing said cell to an effective amount of another pharmaceutical ingredient.
54. (New) The method of claim 53, wherein said other pharmaceutical ingredient is an anti-emetic or anti-diarrheal therapeutic composition.
55. (New) The method of claim 53, wherein said other pharmaceutical ingredient is an agent that overcomes a specific drug resistance mechanism.
56. (New) The method of claim 53, wherein said other pharmaceutical ingredient is another anti-cancer therapeutic agent.
57. (New) A method of killing or inhibiting the growth of a tumor cell resistant to a taxane comprising exposing said cell to an effective amount of a compound of the structure




(b)



58. (New) The method of claim 57, wherein the resistance or refractoriness of said cancer or tumor is mediated through tubulin.
59. (New) The method of claim 57, wherein the resistance or refractoriness of said cancer or tumor is mediated through multidrug resistance.
60. (New) The method of claim 59, wherein said multidrug resistance is mediated through overexpression of an ABC transporter.
61. (New) The method of claim 57, wherein said taxane is paclitaxel.
62. (New) The method of claim 57, wherein said taxane is docetaxel.
63. (New) The method of claim 57, wherein said tumor comprises a solid tumor.
64. (New) The method of claim 63, wherein said solid tumor is selected from: breast cancer, cervical cancer, colorectal cancer, peritoneal cancer, ovarian cancer, bronchial cancer, small cell lung cancer, non-small cell lung cancer, gastric, prostate, and head and neck cancer, or metastases thereof.
65. (New) The method of claim 63, wherein said solid tumor is prostate cancer.
66. (New) The method of claim 63, wherein said solid tumor is breast cancer.
67. (New) The method of claim 63, wherein said solid tumor is ovarian cancer.
68. (New) The method of claim 63, wherein said solid tumor is non-small cell lung cancer.
69. (New) The method of claim 57, wherein said tumor comprises a hematological tumor.
70. (New) The method of claim 57, wherein said method further comprises the further administration of an effective amount of another pharmaceutical ingredient or exposing said cell to an effective amount of another pharmaceutical ingredient.


71. (New) The method of claim 70, wherein said other pharmaceutical ingredient is an anti-emetic or anti-diarrheal therapeutic composition.
72. (New) The method of claim 70, wherein said other pharmaceutical ingredient is an agent that overcomes a specific drug resistance mechanism.
73. (New) The method of claim 70, wherein said other pharmaceutical ingredient is another anti-cancer therapeutic agent.
74. (New) An article of manufacture comprising a pharmaceutical composition and a label which indicates that said pharmaceutical composition can be used for the treatment of an individual suffering from a cancer or tumor resistant or refractory to a taxane, wherein said pharmaceutical composition comprises a compound of the structure



75. (New) The article of manufacture of claim 74, wherein the resistance or refractoriness of said cancer or tumor is mediated through tubulin.
76. (New) The article of manufacture of claim 74, wherein the resistance or refractoriness of said cancer or tumor is mediated through multidrug resistance.
77. (New) The article of manufacture of claim 76, wherein said multidrug resistance is mediated through overexpression of an ABC transporter.
78. (New) The article of manufacture of claim 74, wherein said taxane is paclitaxel.
79. (New) The article of manufacture of claim 74, wherein said taxane is docetaxel.
80. (New) The article of manufacture of claim 74, wherein said tumor comprises a solid tumor.
81. (New) The article of manufacture of claim 80, wherein said solid tumor is selected from: breast cancer, cervical cancer, colorectal cancer, peritoneal cancer, ovarian cancer,

bronchial cancer, small cell lung cancer, non-small cell lung cancer, gastric, prostate, and head and neck cancer, or metastases thereof.

82. (New) The article of manufacture of claim 80, wherein said solid tumor is prostate cancer.
83. (New) The article of manufacture of claim 80, wherein said solid tumor is breast cancer.
84. (New) The article of manufacture of claim 80, wherein said solid tumor is ovarian cancer.
85. (New) The article of manufacture of claim 80, wherein said solid tumor is non-small cell lung cancer.
86. (New) The article of manufacture of claim 74, wherein said tumor comprises a hematological tumor.
87. (New) The article of manufacture of claim 74, wherein said article of manufacture further comprises another pharmaceutical ingredient and/or wherein said label indicates that said pharmaceutical composition can be further administered with an effective amount of another pharmaceutical ingredient.
88. (New) The article of manufacture of claim 87 wherein said other pharmaceutical ingredient is an anti-emetic or anti-diarrheal therapeutic composition.
89. (New) The article of manufacture of claim 87, wherein said other pharmaceutical ingredient is an agent that overcomes a specific drug resistance mechanism.
90. (New) The article of manufacture of claim 87, wherein said other pharmaceutical ingredient is another anti-cancer therapeutic agent.
91. (New) A packaged pharmaceutical comprising a pharmaceutical composition comprising a compound of the structure



wherein said packaged pharmaceutical further comprises instructions to administer an effective amount of the pharmaceutical composition to an individual suffering from a cancer or tumor resistant or refractory to a taxane.

92. (New) The packaged pharmaceutical according to claim 91, wherein the resistance or refractoriness of said cancer or tumor is mediated through tubulin.
93. (New) The packaged pharmaceutical according to claim 91, wherein the resistance or refractoriness of said cancer or tumor is mediated through multidrug resistance.
94. (New) The packaged pharmaceutical according to claim 93, wherein said multidrug resistance is mediated through overexpression of an ABC transporter.
95. (New) The packaged pharmaceutical according to claim 91, wherein said taxane is paclitaxel.
96. (New) The packaged pharmaceutical according to claim 91, wherein said taxane is docetaxel.
97. (New) The packaged pharmaceutical according to claim 91, wherein said tumor comprises a solid tumor.
98. (New) The packaged pharmaceutical according to claim 97, wherein said solid tumor is selected from: breast cancer, cervical cancer, colorectal cancer, peritoneal cancer, ovarian cancer, bronchial cancer, small cell lung cancer, non-small cell lung cancer, gastric, prostate, and head and neck cancer, or metastases thereof.
99. (New) The packaged pharmaceutical according to claim 97, wherein said solid tumor is prostate cancer.
100. (New) The packaged pharmaceutical according to claim 97, wherein said solid tumor is breast cancer.

101. (New) The packaged pharmaceutical according to claim 97, wherein said solid tumor is ovarian cancer.
102. (New) The packaged pharmaceutical according to claim 97, wherein said solid tumor is non-small cell lung cancer.
103. (New) The packaged pharmaceutical according to claim 91, wherein said tumor comprises a hematological tumor.
104. (New) The packaged pharmaceutical according to claim 91, wherein said packaged pharmaceutical further comprises another pharmaceutical ingredient and/or instructions to further administer an effective amount of another pharmaceutical ingredient.
105. (New) The packaged pharmaceutical of claim 104, wherein said other pharmaceutical ingredient is an anti-emetic or anti-diarrheal therapeutic composition.
106. (New) The packaged pharmaceutical of claim 104, wherein said other pharmaceutical ingredient is an agent that overcomes a specific drug resistance mechanism.
107. (New) The packaged pharmaceutical of claim 104, wherein said other pharmaceutical ingredient is another anti-cancer therapeutic agent.